Emergent BioSolutions Pumps Out Bulk Active Drug Product for J&J COVID Vaccine, an Industrial Info Market Brief
Emergent BioSolutions Pumps Out Bulk Active Drug Product for J&J COVID Vaccine, an Industrial Info Market Brief
Attachment: Map
Johnson & Johnson's COVID-19 vaccine has become the third to receive emergency use authorization by the U.S. Food and Drug Administration (FDA). Emergent BioSolutions is busy producing the bulk active drug product for the vaccine, before it is shipped off for "fill and finish" at other plants, including those owned by CMO manufacturer Catalent. In that step, the drug product is thawed, diluted and divided into vials ready for distribution.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- ISPE Names the 2018 Pharmaceutical Facility of the Year Category Awards
- With a Boost from Uncle Sam, U.S. Mid-Atlantic Region Draws $8 Billion in L...
- Baltimore Attracts $5.6 Billion in Construction Activity
- Pharma-Bio 2Q14 Update: $9 Billion in Project Starts Reflects 91% Gain in I...
- France Plans $55 Billion in Windfarms as Offshore Projects Gain Momentum